Welcome to our dedicated page for LeonaBio SEC filings (Ticker: LONA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company focused on metastatic breast cancer and neurodegenerative diseases such as ALS. While recent company communications describe its programs and strategy, formal SEC filings offer detailed legal and financial disclosures about these activities.
Through this page, users can review core periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically discuss LeonaBio’s clinical-stage pipeline, risk factors related to drug development, and information about licensing arrangements like its exclusive global license (excluding Asia and certain Middle Eastern countries) for lasofoxifene from Sermonix Pharmaceuticals, Inc. These filings may also describe the company’s private placement financings of common stock and warrants that are intended to support clinical and regulatory milestones.
Investors can also look for current reports on Form 8-K, which are used to disclose material events such as the company’s name change from Athira Pharma, Inc. to LeonaBio, Inc., adoption of the LONA ticker, significant licensing transactions, or financing events. In addition, proxy statements on Schedule 14A and related documents can provide information on corporate governance and executive compensation.
This platform enhances access to LeonaBio’s regulatory history by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These summaries are designed to help readers quickly interpret lengthy documents, highlight key sections related to the company’s oncology and neurodegeneration programs, and make it easier to locate information about capital raises, licensing agreements, and other material disclosures.
LeonaBio, Inc. President and CEO Mark James Litton reported several equity transactions involving company stock. On March 3, 2026, 22,254 restricted stock units were exercised at $0.00 per share, converting into the same number of common shares and bringing his direct common stock holdings to 63,082 shares.
On March 4, 2026, 5,156 common shares were sold at a weighted-average price of $5.37 per share to cover tax withholding obligations triggered by the RSU vesting under the company’s mandatory “sell to cover” policies; no additional shares were sold. After this tax-related sale, he directly owned 57,926 common shares. Separate irrevocable trusts established for his children each held 656 common shares as indirect ownership.
LeonaBio, Inc.’s chief financial officer reported routine equity activity involving restricted stock units and a small tax-related sale. On March 3, 3,900 restricted stock units vested and converted into the same number of common shares. On March 4, 906 common shares were sold at a weighted-average price of $5.37 solely to cover tax withholding obligations under a mandatory “sell to cover” policy, leaving 15,851 common shares held directly.
LeonaBio, Inc. executive Mark Worthington reported a mix of share transactions tied to vesting equity awards. On March 3, 2026, 5,726 restricted stock units were exercised into the same number of common shares at
On March 4, 2026, 1,328 common shares were sold in an open-market transaction at a weighted-average price of
LeonaBio, Inc. Chief Scientific Officer Kevin Church reported RSU vesting and related share transactions. On March 3, he exercised 5,856 restricted stock units, each converting into one share of common stock at a stated price of $0.00 per share.
Those RSUs, originally granted as 5,856 units on March 3, 2025 and vesting in full one year later, increased his common stock holdings. On March 4, 1,359 common shares were sold in open-market transactions at a weighted-average price of $5.37 per share solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policy.
After these transactions, Church directly held 25,178 shares of LeonaBio common stock.
LeonaBio, Inc.’s chief medical officer Javier San Martin reported equity compensation activity and a related tax sale. On March 3, 2026, 7,418 restricted stock units (RSUs) fully vested and were converted into 7,418 shares of common stock at a stated price of $0.00 per share.
On March 4, 2026, 1,720 shares of common stock were sold in open-market transactions at a weighted-average price of $5.37 per share, solely to cover tax withholding obligations under LeonaBio’s mandatory “sell to cover” policies, and not as a discretionary sale. After these transactions, Javier San Martin directly owned 15,887 shares of LeonaBio common stock.
LeonaBio, Inc. (ATHA) filed a Rule 144 notice to sell 22,254 shares of common stock tied to an equity compensation event.
The filing also reports 2,586 shares sold in the past three months and lists a
LeonaBio, Inc. is asking stockholders to approve several capital and governance proposals at a virtual special meeting on March 18, 2026. The company seeks approval to issue 5,502,402 shares of common stock upon exercise of a pre-funded warrant held by Sermonix, and to allow Sermonix and Perceptive to exercise their warrants even if their ownership exceeds 19.99%, as required by Nasdaq Rule 5635(b). Stockholders are also asked to approve a new 2026 Equity Incentive Plan with an initial reserve of 5,700,000 shares plus an evergreen increase, amend the charter to increase authorized common stock, and permit adjournment if more time is needed to secure votes. If key proposals fail, LeonaBio may owe Sermonix up to
LeonaBio, Inc. has filed a resale registration statement covering up to 5,502,402 shares of common stock that may be sold from time to time by Sermonix Pharmaceuticals and its permitted transferees. These shares are issuable upon exercise of a pre-funded warrant that Sermonix received in connection with a December 2025 license agreement granting LeonaBio exclusive rights to develop and commercialize lasofoxifene in certain territories.
LeonaBio will not receive any proceeds from Sermonix’s resale of the registered shares, but would receive up to approximately $5,502 in gross proceeds if the warrant is fully exercised for cash at an exercise price of $0.001 per share, which it plans to use for working capital and to advance lasofoxifene and other pipeline drug candidates. As of December 31, 2025, 9,335,913 shares of common stock were outstanding, separate from the shares covered by this resale registration.
LeonaBio, Inc. has filed a resale registration covering up to 58,464,567 shares of common stock for potential sale by existing selling stockholders. These shares include stock already issued and shares issuable upon exercise of pre-funded warrants and common warrants that were originally sold in a December 2025 private placement. LeonaBio will not receive proceeds from any resale of shares by these holders, but could receive up to approximately $8,816 from cash exercise of 8,816,684 pre-funded warrants at $0.001 per share and approximately